Glucagon infusion increases rate of purine synthesis de novo in rat liver. 1987

M Itakura, and N Maeda, and M Tsuchiya, and K Yamashita
Division of Endocrinology and Metabolism, University of Tsukuba, Ibaraki, Japan.

Based on the parallel increases of glucagon, the second peak of hepatic cAMP, and the rate of purine synthesis de novo in the prereplicative period in regenerating rat liver after a 70% hepatectomy, it was hypothesized that glucagon is responsible for the increased rate of purine synthesis de novo. To test this hypothesis, the effect of glucagon or dibutyryl cAMP infusion on the rate of purine synthesis de novo in rat liver was studied. Glucagon infusion but not insulin or glucose infusion increased the rate of purine synthesis de novo, which was assayed by [14C]glycine or [14C]formate incorporation, by 2.7- to 4.3-fold. Glucagon infusion increased cAMP concentrations by 4.9-fold and 5-phosphoribosyl-1-pyrophosphate concentrations by 1.5-fold in liver but did not change the specific activity of amidophosphoribosyltransferase (EC 2.4.2.14) or purine ribonucleotide concentrations. Dibutyryl cAMP infusion also increased the rate of purine synthesis de novo by 2.2- to 4.0-fold. Because glucagon infusion increased the rate of purine synthesis de novo in the presence of unchanged purine ribonucleotide concentrations, it is concluded that glucagon after infusion or in animals after a 70% hepatectomy is playing an anabolic role to increase the rate of purine synthesis de novo by increasing cAMP and 5-phosphoribosyl-1-pyrophosphate concentrations.

UI MeSH Term Description Entries
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008115 Liver Regeneration Repair or renewal of hepatic tissue. Liver Regenerations,Regeneration, Liver,Regenerations, Liver
D008297 Male Males
D010754 Phosphoribosyl Pyrophosphate The key substance in the biosynthesis of histidine, tryptophan, and purine and pyrimidine nucleotides. Pyrophosphate, Phosphoribosyl
D011685 Purine Nucleotides Purines attached to a RIBOSE and a phosphate that can polymerize to form DNA and RNA. Nucleotides, Purine
D011687 Purines A series of heterocyclic compounds that are variously substituted in nature and are known also as purine bases. They include ADENINE and GUANINE, constituents of nucleic acids, as well as many alkaloids such as CAFFEINE and THEOPHYLLINE. Uric acid is the metabolic end product of purine metabolism.
D003994 Bucladesine A cyclic nucleotide derivative that mimics the action of endogenous CYCLIC AMP and is capable of permeating the cell membrane. It has vasodilator properties and is used as a cardiac stimulant. (From Merck Index, 11th ed) Dibutyryl Adenosine-3',5'-Monophosphate,Dibutyryl Cyclic AMP,(But)(2) cAMP,Bucladesine, Barium (1:1) Salt,Bucladesine, Disodium Salt,Bucladesine, Monosodium Salt,Bucladesine, Sodium Salt,DBcAMP,Dibutyryl Adenosine 3,5 Monophosphate,N',O'-Dibutyryl-cAMP,N(6),0(2')-Dibutyryl Cyclic AMP,AMP, Dibutyryl Cyclic,Adenosine-3',5'-Monophosphate, Dibutyryl,Cyclic AMP, Dibutyryl,Dibutyryl Adenosine 3',5' Monophosphate,Disodium Salt Bucladesine,Monosodium Salt Bucladesine,N',O' Dibutyryl cAMP,Sodium Salt Bucladesine
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005561 Formates Derivatives of formic acids. Included under this heading are a broad variety of acid forms, salts, esters, and amides that are formed with a single carbon carboxy group. Formic Acids,Acids, Formic
D005934 Glucagon A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511) Glucagon (1-29),Glukagon,HG-Factor,Hyperglycemic-Glycogenolytic Factor,Proglucagon (33-61),HG Factor,Hyperglycemic Glycogenolytic Factor

Related Publications

M Itakura, and N Maeda, and M Tsuchiya, and K Yamashita
January 1973, Verhandlungen der Deutschen Gesellschaft fur Innere Medizin,
M Itakura, and N Maeda, and M Tsuchiya, and K Yamashita
January 1989, Advances in experimental medicine and biology,
M Itakura, and N Maeda, and M Tsuchiya, and K Yamashita
July 1975, Metabolism: clinical and experimental,
M Itakura, and N Maeda, and M Tsuchiya, and K Yamashita
January 1971, Verhandlungen der Deutschen Gesellschaft fur Innere Medizin,
M Itakura, and N Maeda, and M Tsuchiya, and K Yamashita
June 1986, The Journal of pharmacology and experimental therapeutics,
M Itakura, and N Maeda, and M Tsuchiya, and K Yamashita
August 1980, Canadian journal of biochemistry,
M Itakura, and N Maeda, and M Tsuchiya, and K Yamashita
December 1983, Proceedings of the National Academy of Sciences of the United States of America,
M Itakura, and N Maeda, and M Tsuchiya, and K Yamashita
May 1981, Biomedicine / [publiee pour l'A.A.I.C.I.G.],
M Itakura, and N Maeda, and M Tsuchiya, and K Yamashita
January 1984, Advances in experimental medicine and biology,
M Itakura, and N Maeda, and M Tsuchiya, and K Yamashita
January 1982, Biochimica et biophysica acta,
Copied contents to your clipboard!